Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
UK0369, 003 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| UK0369,003 | DRUG | - |
| Cialis (Tadalafil) | DRUG | - |
Inclusion Criteria: * Erectile Dysfunction Exclusion Criteria: * Alpha blockers and Nitrates of any preparation
UK369,003 is an investigational small molecule being developed by Pfizer, Inc. for the treatment of impotence, also known as erectile dysfunction. It is in Phase 2 clinical development and has been studied in patients with this condition.
The specific molecular target of UK369,003 has not been disclosed in the available information. It is a small molecule being developed for the treatment of erectile dysfunction, but its mechanism of action has not been specified.
UK369,003 is being developed by Pfizer, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 2 clinical development for the treatment of erectile dysfunction.
UK369,003 is in Phase 2 clinical development. It has completed one Phase 2 trial, and it is not approved by regulatory authorities. The drug remains investigational and is being studied for the treatment of erectile dysfunction.
UK369,003 has been studied in one completed Phase 2 clinical trial, identified as NCT00174486. This trial assessed the duration of action, safety, and toleration of UK369,003 and Cialis in patients with erectile dysfunction, enrolling 300 male participants aged 18 years and older.
No, UK369,003 is not the same as Cialis. UK369,003 is an investigational drug being developed by Pfizer, while Cialis is a separate medication. The completed clinical trial NCT00174486 compared UK369,003 with Cialis in patients with erectile dysfunction.